GoAI
Get started
ProKidney Corp. logo

ProKidney Corp.

PROK

NASDAQHealthcareBiotechnology

Open in GoAI

Regular session

$1.595

−$0.015 · -0.93%

Aug 24, 11:00 AM ET

PROK company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

42

Fair Value

Momentum

31

Weakening

Sentiment

52

Mixed

Risk resilience

25

High Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

ProKidney Corp. is a biotechnology firm currently in the clinical trial phase, specializing in the development of innovative cell-based treatments. Their flagship product is Renal Autologous Cell Therapy (RAC-T), a unique cellular admixture derived from a patient's own cells. RAC-T is undergoing significant clinical evaluation; it is concurrently in Phase III and Phase II trials for individuals with moderate to severe diabetic kidney disease. Furthermore, the company is conducting a Phase I clinical trial to assess RAC-T's potential for patients born with congenital anomalies affecting the kidneys and urinary tract. The company was established in 2015 and operates from its headquarters in Winston-Salem, North Carolina.

Industry
Biotechnology
Sector
Healthcare
Headquarters
US
CEO
Bruce Culleton
Listed since
Jun 30, 2021
Employees
231

Market position

Day range

Current $1.595

52-week range

Current $1.595

Open
$1.59
Previous close
$1.61
Volume
207.92K
0.18× average
Average volume
1.12M
Average daily volume
Market cap
543.05M USD
Beta
1.72
Market reference 1
50-day average
$1.6546
-3.60% below average
200-day average
$1.9876
-19.75% below average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
576.4M USD
P/E (TTM)
-2.8×
P/B (TTM)
-0.34×
P/S (TTM)
656.68×
EV / EBITDA
-3.99×
Earnings yield
-22.99%
Free cash flow yield
-45.10%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
-252.57%
Operating margin
-21664.55%
Net margin
-10599.76%
Return on equity
6.82%
Return on assets
-20.56%
Return on invested capital
-53.94%

Financial health

Debt / equity
-0×
Current ratio
9.13×
Altman Z-score
3.59
Piotroski F-score
1 of 9

Financial statements

Margin trends

Profitability as a percentage of reported revenue.

Gross marginOperating marginNet margin
Gross, operating, and net margin trends24278%-72434%-169145%-265857%Gross margin, FY2024: 100.00%Gross margin, FY2025: 100.00%Operating margin, FY2024: -241678.95%Operating margin, FY2025: -18477.83%Net margin, FY2024: -80507.89%Net margin, FY2025: -7725.20%FY2021FY2022FY2023FY2024FY2025
Gross margin FY2024 100.00%. Gross margin FY2025 100.00%. Operating margin FY2024 -241678.95%. Operating margin FY2025 -18477.83%. Net margin FY2024 -80507.89%. Net margin FY2025 -7725.20%.

Income trends

Revenue

893K USD+1075.00%

Operating income

−165.01M USD+10.16%

Net income

−68.99M USD-12.75%
Income trends across reported periods19.35M USD−54.48M USD−128.31M USD−202.13M USDRevenue, FY2024: 76K USDRevenue, FY2025: 893K USDOperating income, FY2021: −55.11M USDOperating income, FY2022: −153.01M USDOperating income, FY2023: −151.52M USDOperating income, FY2024: −183.68M USDOperating income, FY2025: −165.01M USDNet income, FY2021: −55.15M USDNet income, FY2022: −108.03M USDNet income, FY2023: −35.47M USDNet income, FY2024: −61.19M USDNet income, FY2025: −68.99M USDFY2021FY2022FY2023FY2024FY2025
Revenue FY2024 76K USD. Revenue FY2025 893K USD. Operating income FY2021 −55.11M USD. Operating income FY2022 −153.01M USD. Operating income FY2023 −151.52M USD. Operating income FY2024 −183.68M USD. Operating income FY2025 −165.01M USD. Net income FY2021 −55.15M USD. Net income FY2022 −108.03M USD. Net income FY2023 −35.47M USD. Net income FY2024 −61.19M USD. Net income FY2025 −68.99M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Revenue893K USD76K USD———
Gross profit893K USD76K USD———
Research and development114.12M USD127.67M USD106.71M USD82.07M USD46.26M USD
Selling, general, and administrative51.78M USD56.08M USD44.82M USD70.94M USD8.86M USD
Operating expenses165.9M USD183.75M USD151.52M USD153.01M USD55.11M USD
Interest income13.81M USD19.75M USD22.08M USD5.98M USD2K USD
Interest expense4K USD9K USD12K USD215K USD—
Depreciation and amortization6.58M USD5.43M USD3.85M USD3.04M USD1.98M USD
Operating income−165.01M USD−183.68M USD−151.52M USD−153.01M USD−55.11M USD
Net income−68.99M USD−61.19M USD−35.47M USD−108.03M USD−55.15M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 3 misses, 2 met estimates
Average EPS surprise
+8.79%
11 comparable reports
Latest EPS result
-0.15
Estimate -0.14 · Miss by 7.14%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.1-0.14-0.17-0.21Q1 '25MissQ2 '25BeatQ3 '25BeatQ4 '25MetQ1 '26BeatQ2 '26MissQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 17, 2025: actual -0.17, estimate -0.14, surprise -21.43%, Miss. Q2 2025, reported May 12, 2025: actual -0.13, estimate -0.16, surprise +18.75%, Beat. Q3 2025, reported Aug 12, 2025: actual -0.13, estimate -0.14, surprise +7.14%, Beat. Q4 2025, reported Nov 10, 2025: actual -0.12, estimate -0.12, surprise 0.00%, Met estimate. Q1 2026, reported Mar 18, 2026: actual -0.14, estimate -0.16, surprise +12.50%, Beat. Q2 2026, reported May 15, 2026: actual -0.14, estimate -0.13, surprise -7.69%, Miss. Q3 2026, reported Aug 10, 2026: actual -0.15, estimate -0.14, surprise -7.14%, Miss. Q4 2026, reported Nov 9, 2026: actual —, estimate -0.12, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates248.35K165.74K83.12K510Q1 '25No estimateQ2 '25No estimateQ3 '25BeatQ4 '25No estimateQ1 '26BeatQ2 '26BeatQ3 '26MissQ4 '26Estimate
Q1 2025, reported Mar 17, 2025: actual 76K USD, estimate —, surprise —, Comparison unavailable. Q2 2025, reported May 12, 2025: actual 230K USD, estimate —, surprise —, Comparison unavailable. Q3 2025, reported Aug 12, 2025: actual 221K USD, estimate 44.25K USD, surprise +399.44%, Beat. Q4 2025, reported Nov 10, 2025: actual 217K USD, estimate —, surprise —, Comparison unavailable. Q1 2026, reported Mar 18, 2026: actual 223K USD, estimate 600 USD, surprise +37066.67%, Beat. Q2 2026, reported May 15, 2026: actual 226K USD, estimate 100.25K USD, surprise +125.44%, Beat. Q3 2026, reported Aug 10, 2026: actual 150K USD, estimate 186.25K USD, surprise -19.46%, Miss. Q4 2026, reported Nov 9, 2026: actual —, estimate 124.6K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Rating distribution

8 ratings
Strong buy00%
Buy675%
Hold113%
Sell113%
Strong sell00%

Recent analyst actions

6 institutions
HC Wainwright & Co.maintainBuy
UBSmaintainBuy
GuggenheimmaintainBuy
CitigroupmaintainBuy
JefferiesmaintainBuy

PROK news

seekingalpha.com

ProKidney: Do-Or-Die Phase 3 Meets A Dwindling Balance Sheet (Rating Downgrade)

ProKidney Corp. is a single-asset biotech with a dwindling cash position and an unproven lead therapy, rilparencel. Phase 2 data for rilparencel is weak, with confounding factors and no robust evidence of efficacy; Phase…

Read source
zacks.com

ProKidney Corp. (PROK) Reports Q2 Loss, Misses Revenue Estimates

ProKidney Corp. (PROK) came out with a quarterly loss of $0.15 per share versus the Zacks Consensus Estimate of a loss of $0.13. This compares to a loss of $0.13 per share a year ago.

Read source
globenewswire.com

ProKidney Appoints Kenneth Locke as Chief Technical Officer

Kenneth Locke joins as Chief Technical Officer, bringing more than 25 years of experience across Chemistry, Manufacturing and Controls (CMC) and Supply Chain as ProKidney progresses toward the potential commercialization…

Read source

PROK peers

Amgen Inc. logo

AMGN

Amgen Inc.

$440.72

+0.32%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$145.71

-0.28%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$547.55

-0.09%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$379.11

+0.08%

Sanofi logo

SNY

Sanofi

$45.6206

-0.50%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$825.22

-1.06%

ETFs holding PROK

Funds reporting this stock among their holdings, ordered by reported position size.

iShares Russell 2000 ETF logoiShares Russell 2000 ETFIWM
Market value
2.72M
Weight
0.00%
AUM
81.62B USD
Expense ratio
0.19%
Price / 1D
$298.42-0.51%
Vanguard Extended Market ETF logoVanguard Extended Market ETFVXF
Market value
1.97M
Weight
0.00%
AUM
93.7B USD
Expense ratio
0.05%
Price / 1D
$243.85-0.68%
Schwab U.S. Small-Cap ETF logoSchwab U.S. Small-Cap ETFSCHA
Market value
806.12K
Weight
0.00%
AUM
23.1B USD
Expense ratio
0.03%
Price / 1D
$34.45-1.11%
iShares Russell 2000 Growth ETF logoiShares Russell 2000 Growth ETFIWO
Market value
654.66K
Weight
0.00%
AUM
15.16B USD
Expense ratio
0.24%
Price / 1D
$383.68-0.95%
Vanguard Russell 2000 ETF logoVanguard Russell 2000 ETFVTWO
Market value
652.96K
Weight
0.00%
AUM
17.4B USD
Expense ratio
0.06%
Price / 1D
$120.65-0.50%
iShares Micro-Cap ETF logoiShares Micro-Cap ETFIWC
Market value
413.74K
Weight
0.03%
AUM
1.53B USD
Expense ratio
0.60%
Price / 1D
$197.38-0.38%
iShares Russell 2000 Value ETF logoiShares Russell 2000 Value ETFIWN
Market value
332.48K
Weight
0.00%
AUM
14.66B USD
Expense ratio
0.24%
Price / 1D
$224.51-0.14%
Virtus Biotech Clinical Trials ETF logoVirtus Biotech Clinical Trials ETFBBC
Market value
269.12K
Weight
0.53%
AUM
51.68M USD
Expense ratio
0.65%
Price / 1D
$53.06-2.58%

Continue in GoAI

Research PROK

research.disclaimer